In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of ...

Persistent abdominal pain, distinct from occasional discomfort, can stem from various digestive issues like IBS or GERD, ...